

ATLAS ACS 2-TIMI 51 ACS - Major bleeding will restrict potential in ACS

<https://marketpublishers.com/r/AF72AB5861DEN.html>

Date: November 2011

Pages: 7

Price: US\$ 140.00 (Single User License)

ID: AF72AB5861DEN

Abstracts

Robust mortality benefit demonstrated by Xarelto in ACS patients, though at the cost of higher major TIMI bleeds (but less fatal bleeds), warrants an approval for sure. Our discussion with cardiologists suggests that the uptake is likely to be slow and the drug would be initially positioned in the high risk patients (with low bleeding risk) and ACS patients presenting with concomitant Atrial Fibrillation (~ 3-10% of the ACS patients). We forecast \$XX in peak sales for Xarelto in ACS and \$XX across all indications (DVT treatment would be the largest single indication).

Contents

COMPANIES MENTIONED

PFE, BMY, Bayer

I would like to order

Product name: ATLAS ACS 2-TIMI 51 ACS - Major bleeding will restrict potential in ACS

Product link: <https://marketpublishers.com/r/AF72AB5861DEN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AF72AB5861DEN.html>